A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC.
Balazs HalmosThomas BurkeChrysostomos KalyvasRalph InsingaKristel VandormaelAndrew FredericksonBilal PiperdiPublished in: Cancers (2020)
These MAIC results suggest that pembrolizumab + chemotherapy leads to a greater clinical benefit vs nivolumab + ipilimumab in patients with PD-L1 TPS ≥1% across multiple endpoints.